Medtronic
(NYSE: MDT)
announced today that it appointed Paolo Di Vincenzo as the president of its Neuromodulation business.
Di Vincenzo’s appointment at Medtronic goes into effect on Oct. 30. In his new role, he holds responsibilities for the overall strategic direction of the company’s neuromodulation business and day-to-day operations.
Neuromodulation is part of Medtronic’s Neurosciences portfolio, comprised of Pain Interventions and Brain Modulation. The unit engineers innovative therapies and technologies to help patients relieve pain, restore function and reclaim movement.
Di Vincenzo joins Medtronic from Smith+Nephew, where he served as SVP and GM of U.S. advanced wound management. Over nine years at the orthopedic giant, he also served in global marketing and leadership roles.
Before Smith+Nephew, Di Vincenzo held a number of marketing leadership roles of increasing responsibility at Systagenix, BD and Roche Diagnostics.
“Paolo is a results-driven leader who puts people first,” said Brett Wall, EVP and president of the Neurosciences portfolio at Medtronic. “I’m thrilled to have him join this team as Neuromodulation moves into the era of personalized medicine with sensing technology. He will play a key role in advancing our capabilities in these areas while driving business execution in alignment with Medtronic’s focus on a performance-driven culture.”